CSL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

CSL şirketinin toplam hissedar öz sermayesi $19.4B ve toplam borcu $10.5B olup, bu da borç-öz sermaye oranını 54.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $38.0B ve $18.6B dir. CSL 'in FAVÖK'ü $3.9B faiz karşılama oranı 8.9 dur. Şirketin $1.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

54.2%

Borç/özkaynak oranı

US$10.52b

Borç

Faiz karşılama oranı	8.9x
Nakit	US$1.66b
Eşitlik	US$19.40b
Toplam yükümlülükler	US$18.62b
Toplam varlıklar	US$38.02b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CSJ 'nin kısa vadeli varlıkları ( $10.8B ) kısa vadeli yükümlülüklerini ( $5.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: CSJ 'un kısa vadeli varlıkları ( $10.8B ) uzun vadeli yükümlülüklerini ( $13.7B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CSJ 'nin net borç/öz sermaye oranı ( 45.7% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CSJ 'nin borç/öz sermaye oranı son 5 yılda 88.4% seviyesinden 54.2% seviyesine düştü.

Borç Kapsamı: CSJ 'nin borcu işletme nakit akışı ( 26.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: CSJ 'in borcuna ilişkin faiz ödemeleri EBIT ( 8.9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

CSL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

New minor risk - Financial position

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

High number of new directors

CSL Limited Provides Financial Guidance for Fiscal 2022

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin